These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21166516)

  • 1. Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer.
    Hinnen KA; van Vulpen M
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):115-23. PubMed ID: 21166516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
    Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
    J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.
    Kaplan A; German L; Chen J; Matzkin H; Mabjeesh NJ
    BJU Int; 2012 Jun; 109(11):1661-5. PubMed ID: 22115188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy.
    Hinnen KA; Battermann JJ; van Roermund JG; Moerland MA; Jürgenliemk-Schulz IM; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1433-8. PubMed ID: 19540075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of perineural invasion on biochemical outcome after permanent prostate iodine-125 brachytherapy.
    Piña AG; Crook JM; Kwan P; Borg J; Ma C
    Brachytherapy; 2010; 9(3):213-8. PubMed ID: 20022565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience with 125I brachytherapy as a radical treatment for prostate cancer at the Russian X-ray Radiology Research Center].
    Kaprin AD; Milenin KN; Ivanov SA; Tsybul'skiĭ AD; Gerasimov AA
    Vestn Rentgenol Radiol; 2011; (1):26-8. PubMed ID: 21598469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive 125I prostate brachytherapy implant for low-risk prostate cancer in a patient with an ileal pouch-anal anastomosis: a case report.
    Miles EF; Nelson JW
    Brachytherapy; 2011; 10(2):117-20. PubMed ID: 20688577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.